244 related articles for article (PubMed ID: 24857059)
1. The value of EGFRvIII as the target for glioma vaccines.
Lowenstein PR; Castro MG
Am Soc Clin Oncol Educ Book; 2014; ():42-50. PubMed ID: 24857059
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for glioma: from illusion to realistic prospects?
Dietrich PY; Dutoit V; Walker PR
Am Soc Clin Oncol Educ Book; 2014; ():51-9. PubMed ID: 24857060
[TBL] [Abstract][Full Text] [Related]
3. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
4. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
[TBL] [Abstract][Full Text] [Related]
5. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
Batich KA; Sampson JH
Expert Opin Pharmacother; 2014 Oct; 15(14):2047-61. PubMed ID: 25139628
[TBL] [Abstract][Full Text] [Related]
6. Glioma-specific antigens for immune tumor therapy.
Skog J
Expert Rev Vaccines; 2006 Dec; 5(6):793-802. PubMed ID: 17184218
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based immunotherapeutic approaches to glioma: a review.
Yamanaka R; Itoh K
Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
[TBL] [Abstract][Full Text] [Related]
8. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
9. Novel chemotherapeutics and other therapies for treating high-grade glioma.
Kang JH; Adamson C
Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
[TBL] [Abstract][Full Text] [Related]
11. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
13. Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events.
Lowenstein PR
J Clin Oncol; 2010 Nov; 28(31):4670-3. PubMed ID: 20921460
[No Abstract] [Full Text] [Related]
14. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Choi BD; Kuan CT; Cai M; Archer GE; Mitchell DA; Gedeon PC; Sanchez-Perez L; Pastan I; Bigner DD; Sampson JH
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):270-5. PubMed ID: 23248284
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of Brain Tumors.
Dutoit V; Migliorini D; Walker PR; Dietrich PY
Prog Tumor Res; 2015; 42():11-21. PubMed ID: 26376741
[TBL] [Abstract][Full Text] [Related]
16. Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination.
Yu JS; Luptrawan A; Black KL; Liu G
Clin Neurosurg; 2006; 53():345-51. PubMed ID: 17380773
[TBL] [Abstract][Full Text] [Related]
17. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for glioma: getting closer to the clinical arena?
Finocchiaro G; Pellegatta S
Curr Opin Neurol; 2011 Dec; 24(6):641-7. PubMed ID: 22027543
[TBL] [Abstract][Full Text] [Related]
19. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
[TBL] [Abstract][Full Text] [Related]
20. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma.
Shevtsov MA; Nikolaev BP; Yakovleva LY; Parr MA; Marchenko YY; Eliseev I; Yudenko A; Dobrodumov AV; Zlobina O; Zhakhov A; Ischenko AM; Pitkin E; Multhoff G
J Control Release; 2015 Dec; 220(Pt A):329-340. PubMed ID: 26522072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
